The strategic objective of WP4 is to develop a comprehensive and
full in silico pharmacokinetic (PK) model of hydrocortisone that
can be used to inform rational formulation optimisation (in
conjunction with WP3) and to predict drug absorption and
disposition in the different paediatric age groups targeted.

Work Package 4

WP4 will be led by SimCyp Ltd, with input from Diurnal Ltd. The
pharmacokinetic modelling will be used to predict drug absorption
and disposition in the different paediatric age groups targeted
(neonates and infants), with the goal of optimising clinical trial
design to minimise the number of patients required for the clinical
study (WP5).

Work Package 4

4.1 Review and collate physiological and
biochemical data

4.2 Preclinical and clinical pharmacokinetic data
and the development of compound files